Weijing Sun Selected Research

trifluridine tipiracil drug combination

1/2021	A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
1/2019	Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Weijing Sun Research Topics

Disease

58	Neoplasms (Cancer) 03/2024 - 08/2002
18	Adenocarcinoma 01/2023 - 12/2004
17	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 08/2002
13	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 07/2004
8	Stomach Neoplasms (Stomach Cancer) 12/2021 - 04/2007
7	Colonic Neoplasms (Colon Cancer) 01/2022 - 02/2005
7	Pancreatic Neoplasms (Pancreatic Cancer) 04/2021 - 02/2011
6	Disease Progression 10/2018 - 08/2005
4	Carcinoma (Carcinomatosis) 01/2019 - 12/2004
4	Melanoma (Melanoma, Malignant) 01/2018 - 01/2017
4	Neutropenia 06/2013 - 04/2003
3	Neoplasm Metastasis (Metastasis) 03/2024 - 01/2011
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 02/2024 - 07/2015
3	Cholangiocarcinoma 01/2021 - 04/2011
3	Inflammation (Inflammations) 01/2021 - 04/2017
2	Rectal Neoplasms (Rectal Cancer) 12/2020 - 03/2020
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2019 - 04/2017
2	Microsatellite Instability 01/2019 - 11/2016
2	Mastitis 12/2017 - 04/2017
2	Hypersensitivity (Allergy) 07/2006 - 11/2003
2	Thrombocytopenia (Thrombopenia) 02/2005 - 04/2003
1	Cardiotoxicity 12/2023
1	Residual Neoplasm 06/2023
1	Circulating Neoplastic Cells 01/2023
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2023
1	Testicular Neoplasms (Testicular Cancer) 01/2022
1	Infections 01/2022
1	Esophageal Neoplasms (Esophageal Cancer) 01/2022
1	Renal Cell Carcinoma (Grawitz Tumor) 12/2021

Drug/Important Bio-Agent (IBA)

11	Biomarkers (Surrogate Marker)IBA 02/2024 - 07/2004
11	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 08/2002
8	Immune Checkpoint InhibitorsIBA 01/2023 - 07/2015
8	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 04/2003
8	Gemcitabine FDA Link 01/2019 - 09/2003
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2024 - 10/2012
7	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2023 - 07/2006
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2014 - 09/2003
6	Bevacizumab (Avastin)FDA Link 07/2015 - 01/2010
5	pembrolizumabIBA 01/2023 - 10/2018
5	Capecitabine (Xeloda)FDA Link 12/2014 - 02/2005
4	Leucovorin (Folinic Acid)FDA Link 01/2023 - 05/2005
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2014
4	Sorafenib (BAY 43-9006)FDA Link 06/2018 - 02/2009
4	Long Noncoding RNAIBA 01/2018 - 01/2017
4	Angiogenesis InhibitorsIBA 07/2015 - 02/2009
3	durvalumabIBA 02/2024 - 10/2019
3	DNA (Deoxyribonucleic Acid)IBA 06/2023 - 01/2021
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 01/2020
3	PlatinumIBA 01/2022 - 07/2006
3	Cetuximab (Erbitux)FDA Link 01/2022 - 01/2010
3	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 02/2005
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 11/2003
3	AntigensIBA 01/2022 - 10/2020
3	regorafenibIBA 01/2019 - 01/2014
3	B7-H1 AntigenIBA 10/2018 - 08/2016
3	afliberceptIBA 07/2015 - 10/2012
3	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2011 - 08/2005
2	cabozantinibIBA 02/2024 - 01/2023
2	Panitumumab (Vectibix)FDA Link 01/2022 - 01/2010
2	VaccinesIBA 01/2022 - 01/2019
2	folfirinoxIBA 04/2021 - 06/2017
2	trifluridine tipiracil drug combinationIBA 01/2021 - 01/2019
2	Cancer VaccinesIBA 01/2021 - 09/2014
2	Tyrosine Kinase InhibitorsIBA 08/2020 - 06/2018
2	RamucirumabIBA 07/2015 - 12/2013
2	Monoclonal AntibodiesIBA 12/2013 - 11/2013
2	Polyvinyl AlcoholIBA 04/2011 - 01/2011
2	Ethiodized Oil (Ethiodol)FDA Link 04/2011 - 01/2011
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 04/2011 - 01/2011
2	Epirubicin (Ellence)FDA LinkGeneric 03/2011 - 12/2004
1	Circulating Tumor DNAIBA 06/2023
1	lutetium Lu 177 dotatateIBA 01/2023
1	Peptide Receptors (Peptide Receptor)IBA 01/2023
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2023
1	niraparibIBA 01/2023
1	Radioisotopes (Radionuclides)IBA 01/2023
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	Azacitidine (5 Azacytidine)FDA Link 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 04/2021
1	Losartan (Cozaar)FDA LinkGeneric 04/2021
1	Angiotensin Receptor AntagonistsIBA 04/2021
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021

Therapy/Procedure

46	Therapeutics 01/2023 - 01/2003
22	Drug Therapy (Chemotherapy) 03/2024 - 08/2002
8	Immunotherapy 01/2021 - 09/2014
4	Chemoradiotherapy 01/2022 - 01/2019
4	Radiotherapy 01/2022 - 12/2004
4	Neoadjuvant Therapy 04/2021 - 04/2005
3	Adjuvant Chemotherapy 06/2023 - 05/2018
3	Molecular Targeted Therapy 01/2019 - 01/2003
2	Precision Medicine 01/2023 - 05/2018
1	PC protocol 01/2022
1	Immunomodulation 01/2022
1	Esophagectomy 01/2022